Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Efficacy and Safety of Induction Therapy in Kidney Transplantation: A Network Meta-Analysis.

Hwang SD, Lee JH, Lee SW, Park KM, Kim JK, Kim MJ, Song JH.

Transplant Proc. 2018 May;50(4):987-992. doi: 10.1016/j.transproceed.2018.01.022.

PMID:
29731098
2.

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):789-800. doi: 10.1212/WNL.0000000000005345.

PMID:
29686117
3.

Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.

Croteau D, Flowers C, Kulick CG, Brinker A, Kortepeter CM.

Neurology. 2018 May 1;90(18):e1548-e1552. doi: 10.1212/WNL.0000000000005422. Epub 2018 Mar 30.

PMID:
29602912
4.

Medicines Used for Multiple Sclerosis – A Health Technology Assessment [Internet].

Couto E, Hamidi V, Ringerike T, Odgaard-Jensen J, Harboe I, Klemp M.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016 Feb.

5.

A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.

Hamidi V, Couto E, Ringerike T, Klemp M.

J Clin Med Res. 2018 Feb;10(2):88-105. doi: 10.14740/jocmr3168w. Epub 2017 Dec 30.

6.

Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.

Zhang J, Shi S, Zhang Y, Luo J, Xiao Y, Meng L, Yang X.

Cochrane Database Syst Rev. 2017 Nov 27;11:CD010968. doi: 10.1002/14651858.CD010968.pub2. Review.

PMID:
29178444
7.

Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.

Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL.

Curr Med Res Opin. 2017 Nov 28:1-11. doi: 10.1080/03007995.2017.1407303. [Epub ahead of print]

PMID:
29149804
8.

Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis.

Shao M, Tian T, Zhu X, Ming Y, Iwakiri Y, Ye S, Ye Q.

Oncotarget. 2017 Aug 2;8(39):66426-66437. doi: 10.18632/oncotarget.19815. eCollection 2017 Sep 12.

9.
10.

Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation.

van der Zwan M, Baan CC, van Gelder T, Hesselink DA.

Clin Pharmacokinet. 2018 Feb;57(2):191-207. doi: 10.1007/s40262-017-0573-x. Review.

11.

Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.

Benden C, Haughton M, Leonard S, Huber LC.

J Heart Lung Transplant. 2017 Sep;36(9):921-933. doi: 10.1016/j.healun.2017.05.030. Epub 2017 May 29.

PMID:
28662986
12.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.

13.

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review.

Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T.

Autoimmun Rev. 2017 Jun;16(6):658-665. doi: 10.1016/j.autrev.2017.04.010. Epub 2017 Apr 17. Review.

14.

Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients.

Vázquez L, Salavert M, Gayoso J, Lizasoaín M, Ruiz Camps I, Di Benedetto N; Study Group of Risk Factors for IFI using the Delphi Method.

Rev Esp Quimioter. 2017 Apr;30(2):103-117. Epub 2017 Feb 14.

15.

Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options.

Matutes E.

Expert Rev Hematol. 2017 Mar;10(3):251-258. doi: 10.1080/17474086.2017.1284585. Epub 2017 Jan 29. Review.

PMID:
28128670
16.

Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.

Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC.

Cochrane Database Syst Rev. 2017 Jan 11;1:CD004759. doi: 10.1002/14651858.CD004759.pub2. Review.

PMID:
28073178
17.

Biological Drugs in Guillain-Barré Syndrome: An Update.

Motamed-Gorji N, Matin N, Tabatabaie O, Pavone P, Romano C, Falsaperla R, Vitaliti G.

Curr Neuropharmacol. 2017;15(7):938-950. doi: 10.2174/1570159X14666161213114904. Review.

18.

Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.

Deleu D, Mesraoua B, El Khider H, Canibano B, Melikyan G, Al Hail H, Mhjob N, Bhagat A, Ibrahim F, Hanssens Y.

Curr Med Res Opin. 2017 Mar;33(3):439-458. doi: 10.1080/03007995.2016.1261818. Epub 2016 Dec 31. Review.

PMID:
27892723
19.

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.

Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M.

Mult Scler Relat Disord. 2016 Sep;9:23-30. doi: 10.1016/j.msard.2016.06.001. Epub 2016 Jun 8. Review.

PMID:
27645339
20.

ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.

Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Bretagne S, Cordonnier C; 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN).

J Antimicrob Chemother. 2016 Sep;71(9):2397-404. doi: 10.1093/jac/dkw157. Epub 2016 May 12.

PMID:
27550992

Supplemental Content

Loading ...
Support Center